(Q24200322)

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline as maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline for smoking cessation in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Adherence to varenicline in the COMPASS smoking cessation intervention trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Smoking outcome by psychiatric history after behavioral and varenicline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Behavioral counseling and varenicline treatment for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A longer course of varenicline therapy improves smoking cessation rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline for smoking cessation: a placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Placebo-controlled trial of cytisine for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline and bupropion sustained-release combination therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Combination treatment with varenicline and nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A preliminary investigation of varenicline for heavy drinking smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A pilot clinical trial of varenicline for smoking cessation in black smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

An uncontrolled trial of cytisine (Tabex) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Interventions for smokeless tobacco use cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Cytisine for smoking cessation: a literature review and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Cytisine for smoking cessation: a research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Neuropharmacology and potential efficacy of new treatments for tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Advances in pharmacotherapy for tobacco dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Smoking at age 18-20 and suicide during 26 years of follow-up-how can the association be explained?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

The need for dissemination of evidence-based results from research on nicotine and tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Antidepressants for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Discontinued psychiatric drugs in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Cigarettes and suicide: a prospective study of 50,000 men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Suicidal behavior and depression in smoking cessation treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Use of knock-out mice to determine the molecular basis for the actions of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Telephone counselling for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Nicotine replacement therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Cytisine's potential to be used as a traditional healing method to help indigenous people stop smoking: a qualitative study with Māori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Australia's experience with varenicline: usage, costs and adverse reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Outcome criteria in smoking cessation trials: proposal for a common standard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Is varenicline effectiveness declining in randomized trials?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Comment and reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Smoking is a disease and smokers are patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

What justifies a placebo-controlled trial of Varenicline for smoking cessation in patients with COPD?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB6

7 January 2021

10.1002/14651858.CD006103.PUB6

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22513936

1 reference

Consolidated OpenCitations Corpus – April 2017